Coverage Limitations for Use of Urine Drug Testing in a State Medicaid Program
Open Access
- 1 May 2026
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2611711
Abstract
Importance: Urine drug testing (UDT) is commonly used in substance use disorder (SUD) treatment. However, there is little evidence to guide optimal use of UDT and growing concern that some UDT may represent low-value care. Objective: To determine whether a statewide policy limiting Medicaid reimbursement for UDT is associated with testing frequency, expenditures, and clinical outcomes. Design, Setting, and Participants: This serial cross-sectional study was performed among Louisiana Medicaid beneficiaries between July 1, 2017, and February 29, 2020. Data were analyzed from November 1, 2024, to November 30, 2025. For each outcome, best-fit lines for pre-enactment trends were constructed and used to estimate postenactment trends, which were then compared with observed trends. The 3-way interaction of time by intervention period by outcome was analyzed to assess changes for each UDT utilization outcome compared with a matched control procedure (colonoscopy). Concomitant trends in overdose encounters and prescription of medications for opioid use disorder (MOUD) were also assessed. Exposure: Statewide policy limiting Medicaid reimbursement for UDT enacted in July 2019. Colonoscopy rates were used as a temporal comparison procedure. Main Outcomes and Measures: Outcomes included rates of monthly UDT (total, presumptive, and definitive) and expenditures per 1000 beneficiaries for 24 months before and 7 months after policy enactment. Results: The sample included a total of 900 678 unique Medicaid-eligible beneficiaries, 536 841 (59.6%) of whom were female and 606 012 (67.3%) were younger than 40 years. Following policy enactment, the monthly rate of change for total UDT utilization decreased from 0.67 (95% CI, 0.48- 0.85) to −1.03 (95% CI, −1.65 to −0.40) tests per month per 1000 beneficiaries (difference, −1.70 [95% CI, −2.34 to −1.06] tests per month per 1000 beneficiaries); presumptive UDT decreased from 0.42 (95% CI, 0.30-0.53) to −0.63 (95% CI, −0.92 to −0.35) tests per month per 1000 beneficiaries (difference, −1.05 [95% CI, −1.36 to −0.74] tests per month per 1000 beneficiaries); and definitive UDT decreased from 0.25 (95% CI, 0.17-0.34) to −0.39 (95% CI, −0.97 to 0.18) tests per month per 1000 beneficiaries (difference, −0.65 [95% CI, −1.23 to −0.07] tests per month per 1000 beneficiaries). These decreases were all statistically significant compared with colonoscopy (all P < .05). UDT expenditures also significantly decreased, totaling an estimated $14.8 million in savings during the 7-month postenactment period. The policy change was not associated with reduced MOUD receipt or increased overdose encounters. Conclusion and Relevance: In this cross-sectional study, a state policy limiting reimbursement for UDT was associated with significant reductions in UDT utilization and expenditures. Future research and policymaking should investigate ways to optimize UDT for patient health while reducing low-value care.Keywords
This publication has 32 references indexed in Scilit:
- Effect of Incentives for Alcohol Abstinence in Partnership With 3 American Indian and Alaska Native CommunitiesJAMA Psychiatry, 2021
- Treatment of Alcohol Use DisorderJAMA, 2021
- The rewarding recovery study: a randomized controlled trial of incentives for alcohol and drug abstinence with a rural American Indian communityAddiction, 2020
- A Successful but Underused Strategy for Reducing Low-Value Care: Stop Paying for ItJAMA Internal Medicine, 2020
- Free trade and opioid overdose death in the United StatesSSM - Population Health, 2019
- Access to Treatment for Alcohol Use Disorder at US Health Centers: a National StudyJournal of General Internal Medicine, 2018
- Appropriate Use of Drug Testing in Clinical Addiction MedicineJournal of Addiction Medicine, 2017
- Primary Care Providers’ Experiences with Urine Toxicology Tests to Manage Prescription Opioid Misuse and Substance Use among Chronic Noncancer Pain Patients in Safety Net Health Care SettingsSubstance Abuse, 2016
- Contingency management delivered by community therapists in outpatient settingsDrug and Alcohol Dependence, 2011
- Contingency management: what it is and why psychiatrists should want to use itThe Psychiatrist, 2011